EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TAZ facilitates breast tumor growth by promoting an immune‐suppressive tumor microenvironment

Anat Gershoni iD, Ori Hassin, Nishanth Belugali Nataraj, Sivan Baruch, Adi Avioz-Seligman, Anna Chiara Pirona, Liat Fellus-Alyagor, Tomer Meir Salame, Saptaparna Mukherjee, Giuseppe Mallel, Yosef Yarden, Yael Aylon iD und 1 weitere

Molecular Oncology · 2023

DOI: 10.1002/1878-0261.13525 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Anat Gershoni und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Transcriptional Coactivator with PDZ-Binding Motif Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, The Moross Integrated Cancer Center, The Robert Bosch Stiftung GmbH and the Berthold Leibinger Stiftung GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The core Hippo pathway module consists of a tumour‐suppressive kinase cascade that inhibits the transcriptional coactivators Yes‐associated protein (YAP) and WW domain‐containing transcription regulator protein 1 (WWTR1; also known as TAZ). When the Hippo pathway is downregulated, as often occurs in breast cancer, YAP/TAZ activity is induced. To elaborate the roles of TAZ in triple‐negative breast cancer (TNBC), we depleted Taz in murine TNBC 4T1 cells, using either CRISPR/Cas9 or small hairpin RNA (shRNA). TAZ‐depleted cells and their controls, harbouring wild‐type levels of TAZ, were orthotopically injected into the mammary fat pads of syngeneic BALB/c female mice, and mice were monitored for tumour growth. TAZ depletion resulted in smaller tumours compared to the tumours generated by control cells, in line with the notion that TAZ functions as an oncogene in breast cancer. Tumours, as well as their corresponding in vitro cultured cells, were then subjected to gene expression profiling by RNA sequencing (RNA‐seq). Interestingly, pathway analysis of the RNA‐seq data indicated a TAZ‐dependent enrichment of ‘Inflammatory Response’, a pathway correlated with TAZ expression levels also in human breast cancer tumours. Specifically, the RNA‐seq analysis predicted a significant depletion of regulatory T cells (Tregs) in TAZ‐deficient tumours, which was experimentally validated by the staining of tumour sections and by quantitative cytometry by time of flight (CyTOF). Strikingly, the differences in tumour size were completely abolished in immune‐deficient mice, demonstrating that the immune‐modulatory capacity of TAZ is critical for its oncogenic activity in this setting. Cytokine array analysis of conditioned medium from cultured cells revealed that TAZ increased the abundance of a small group of cytokines, including plasminogen activator inhibitor 1 (Serpin E1; also known as PAI‐1), CCN family member 4 (CCN4; also known as WISP‐1) and interleukin‐23 (IL‐23), suggesting a potential mechanistic explanation for its in vivo immunomodulatory effect. Together, our results imply that TAZ functions in a non‐cell‐autonomous manner to modify the tumour immune microenvironment and dampen the anti‐tumour immune response, thereby facilitating tumour growth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsTranscriptional Coactivator with PDZ-Binding Motif ProteinsAnimalsFemaleHumansMiceHippo Signaling PathwayIntracellular Signaling Peptides and ProteinsTranscription FactorsTumor Microenvironment

Stichwörter der Autor:innen

Hippo pathwayTAZTregsbreast cancer

Substanzen

Intracellular Signaling Peptides and ProteinsTranscription FactorsWWTR1 protein, humanTranscriptional Coactivator with PDZ-Binding Motif Proteins

Autor:innen und Institutionen

  • Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel.
  • Flow Cytometry Unit, Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.

ORCID-Profile: Anat Gershoni, Yael Aylon, Moshe Oren

Förderung

  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  • The Moross Integrated Cancer Center
  • The Robert Bosch Stiftung GmbH and the Berthold Leibinger Stiftung GmbH
  • The United States-Israel Binational Science Foundation

Zitieren

APA

Gershoni, A., Hassin, O., Nataraj, N. B., Baruch, S., Avioz-Seligman, A., Pirona, A. C., Fellus-Alyagor, L., Meir Salame, T., Mukherjee, S., Mallel, G., Yarden, Y., Aylon, Y., & Oren, M. (2023). TAZ facilitates breast tumor growth by promoting an immune‐suppressive tumor microenvironment. Molecular Oncology. https://doi.org/10.1002/1878-0261.13525

Vancouver

Gershoni A, Hassin O, Nataraj NB, Baruch S, Avioz-Seligman A, Pirona AC, et al. TAZ facilitates breast tumor growth by promoting an immune‐suppressive tumor microenvironment. Molecular Oncology. 2023. doi:10.1002/1878-0261.13525

BibTeX
@article{Gershoni2023,
  author = {Gershoni, Anat and Hassin, Ori and Nataraj, Nishanth Belugali and Baruch, Sivan and Avioz-Seligman, Adi and Pirona, Anna Chiara and Fellus-Alyagor, Liat and Meir Salame, Tomer and Mukherjee, Saptaparna and Mallel, Giuseppe and Yarden, Yosef and Aylon, Yael and Oren, Moshe},
  title = {TAZ facilitates breast tumor growth by promoting an immune‐suppressive tumor microenvironment},
  journal = {Molecular Oncology},
  year = {2023},
  doi = {10.1002/1878-0261.13525}
}
Kostenlos starten →